10,11-Dihydroxycarbamazepine (BioDeep_00000002151)

 

Secondary id: BioDeep_00001869901

human metabolite Endogenous blood metabolite Chemicals and Drugs


代谢物信息卡片


(9S,10S)-9,10-dihydroxy-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboximidic acid

化学式: C15H14N2O3 (270.10043740000003)
中文名称:
谱图信息: 最多检出来源 Macaca mulatta(otcml) 0.26%

分子结构信息

SMILES: C1=CC=C2C(=C1)C(C(C3=CC=CC=C3N2C(=O)N)O)O
InChI: InChI=1S/C15H14N2O3/c16-15(20)17-11-7-3-1-5-9(11)13(18)14(19)10-6-2-4-8-12(10)17/h1-8,13-14,18-19H,(H2,16,20)

描述信息

10,11-Dihydroxycarbamazepine, also called carbamazepine diol, is a metabolite of both carbamazepine and oxcarbazepine. Carbamazepine (CBZ) is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia. Oxcarbazepine is an anticonvulsant and mood-stabilizing drug, used primarily in the treatment of epilepsy. It is also used to treat anxiety and mood disorders, and benign motor tics. (Wikipedia)
CONFIDENCE standard compound; INTERNAL_ID 8581
CONFIDENCE standard compound; INTERNAL_ID 2668
CONFIDENCE standard compound; INTERNAL_ID 4109

同义名列表

18 个代谢物同义名

(9S,10S)-9,10-dihydroxy-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboximidic acid; (-)-(S,S)-trans-10,11-Dihydro-10,11-dihydroxy-5H-dibenzo[b,F]azepine-5-carboxamide; 10,11-Dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide, (trans-(+-))-isomer; 10,11-Dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide, (10S,trans)-isomer; 10,11-Dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide, (trans)-isomer; 10,11-Dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide, (cis)-isomer; 5,6-dihydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; 10,11-Dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide; 10,11-Dihydro-10,11-transdihydroxycarbamazepine; 10,11-Dihydro-10,11-dihydroxycarbamazepine; 10,11-Dihydroxy-10,11-dihydrocarbamazepine; Carbamazepine-10,11-transdiol; 10,11-Dihydroxycarbamazepine; Carbamazepine-10,11-diol; Carbazepine 10,11-diol; Dihydroxycarbazepine; CBZ-Diol; CBZD



数据库引用编号

21 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Elena Brezina, Carsten Prasse, Johannes Meyer, Harald Mückter, Thomas A Ternes. Investigation and risk evaluation of the occurrence of carbamazepine, oxcarbazepine, their human metabolites and transformation products in the urban water cycle. Environmental pollution (Barking, Essex : 1987). 2017 Jun; 225(?):261-269. doi: 10.1016/j.envpol.2016.10.106. [PMID: 28408188]
  • Vasilios Kimiskidis, Marios Spanakis, Ioannis Niopas, Dimitrios Kazis, Chrysi Gabrieli, Feras Imad Kanaze, Daniil Divanoglou. Development and validation of a high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2007 Jan; 43(2):763-8. doi: 10.1016/j.jpba.2006.07.047. [PMID: 16959463]
  • Yukiko Nakajima, Yoshiro Saito, Kisho Shiseki, Hiromi Fukushima-Uesaka, Ryuichi Hasegawa, Shogo Ozawa, Kenji Sugai, Masaaki Katoh, Osamu Saitoh, Teiichi Ohnuma, Mitsuru Kawai, Taisuke Ohtsuki, Chieko Suzuki, Narihiro Minami, Hideo Kimura, Yu-ichi Goto, Naoyuki Kamatani, Nahoko Kaniwa, Jun-ichi Sawada. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. European journal of clinical pharmacology. 2005 Mar; 61(1):25-34. doi: 10.1007/s00228-004-0878-1. [PMID: 15692831]
  • N Guénault, P Odou, H Robert. Increase in dihydroxycarbamazepine serum levels in patients co-medicated with oxcarbazepine and lamotrigine. European journal of clinical pharmacology. 2003 Dec; 59(10):781-2. doi: 10.1007/s00228-003-0686-z. [PMID: 14576966]
  • S Härtter, B Jensen, C Hiemke, M Leal, H Weigmann, K Unger. Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of carbamazepine and its main metabolites. Journal of chromatography. B, Biomedical sciences and applications. 1998 Aug; 712(1-2):253-8. doi: 10.1016/s0378-4347(98)00169-8. [PMID: 9698248]
  • L E Riad, R J Sawchuk. A partial area difference analysis for estimating elimination rate constants and distribution volumes of metabolites. Journal of pharmaceutical sciences. 1998 Jun; 87(6):769-73. doi: 10.1021/js970321h. [PMID: 9607957]
  • I Bernus, R G Dickinson, W D Hooper, M J Eadie. The mechanism of the carbamazepine-valproate interaction in humans. British journal of clinical pharmacology. 1997 Jul; 44(1):21-7. doi: 10.1046/j.1365-2125.1997.00607.x. [PMID: 9241092]
  • D A Svinarov, C E Pippenger. Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication. Therapeutic drug monitoring. 1996 Dec; 18(6):660-5. doi: 10.1097/00007691-199612000-00006. [PMID: 8946662]
  • S Eto, N Tanaka, H Noda, A Noda. Chiral separation of 10,11-dihydro-10, 11-trans-dihydroxycarbamazepine, a metabolite of carbamazepine with two asymmetric carbons, in human serum. Journal of chromatography. B, Biomedical applications. 1996 Mar; 677(2):325-30. doi: 10.1016/0378-4347(95)00454-8. [PMID: 8704937]
  • H Liu, M R Delgado. A comprehensive study of the relation between serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites with age, weight, dose, and clearances in epileptic children. Epilepsia. 1994 Nov; 35(6):1221-9. doi: 10.1111/j.1528-1157.1994.tb01793.x. [PMID: 7988515]
  • H Liu, M R Delgado. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites. Therapeutic drug monitoring. 1994 Oct; 16(5):469-76. doi: 10.1097/00007691-199410000-00005. [PMID: 7846744]
  • H Liu, M R Delgado. The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children. Epilepsy research. 1994 Mar; 17(3):257-69. doi: 10.1016/0920-1211(94)90056-6. [PMID: 8013448]
  • M C Rouan, J B Lecaillon, J Godbillon, F Menard, T Darragon, P Meyer, O Kourilsky, D Hillion, J C Aldigier, P Jungers. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. European journal of clinical pharmacology. 1994; 47(2):161-7. doi: 10.1007/bf00194967. [PMID: 7859804]
  • I Bernus, R G Dickinson, W D Hooper, M J Eadie. Early stage autoinduction of carbamazepine metabolism in humans. European journal of clinical pharmacology. 1994; 47(4):355-60. doi: 10.1007/bf00191168. [PMID: 7875188]
  • H Liu, M Delgado, S T Iannaccone, L J Forman, C M Eggers. Determination of total and free carbamazepine and the principal metabolites in serum by high-performance liquid chromatography with photodiode-array detection. Therapeutic drug monitoring. 1993 Aug; 15(4):317-27. doi: 10.1097/00007691-199308000-00010. [PMID: 8236368]
  • R S Moosa, M L McFadyen, R Miller, J Rubin. Carbamazepine and its metabolites in neuralgias: concentration-effect relations. European journal of clinical pharmacology. 1993; 45(4):297-301. doi: 10.1007/bf00265944. [PMID: 8299659]
  • T B Kudriakova, L A Sirota, G I Rozova, V A Gorkov. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. British journal of clinical pharmacology. 1992 Jun; 33(6):611-5. doi: 10.1111/j.1365-2125.1992.tb04089.x. [PMID: 1389933]
  • M C Rouan, J Campestrini, V Le Clanche, J B Lecaillon, J Godbillon. Automated microanalysis of carbamazepine and its epoxide and trans-diol metabolites in plasma by column liquid chromatography. Journal of chromatography. 1992 Jan; 573(1):65-8. doi: 10.1016/0378-4347(92)80475-6. [PMID: 1564108]
  • P H Mogensen, L Jórgensen, J Boas, M Dam, A Vesterager, G Flesch, P K Jensen. Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites. Acta neurologica Scandinavica. 1992 Jan; 85(1):14-7. doi: 10.1111/j.1600-0404.1992.tb03989.x. [PMID: 1546529]
  • W Sunaoshi, H Miura, S Takanashi, H Shirai, N Hosoda. Influence of concurrent administration of sodium valproate on the plasma concentrations of carbamazepine and its epoxide and diol metabolites. The Japanese journal of psychiatry and neurology. 1991 Jun; 45(2):474-7. doi: 10.1111/j.1440-1819.1991.tb02525.x. [PMID: 1762252]
  • R Hartley, W I Forsythe, B McLain, P C Ng, M D Lucock. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Clinical pharmacokinetics. 1991 Mar; 20(3):237-46. doi: 10.2165/00003088-199120030-00005. [PMID: 2025982]
  • F Albani, W H Theodore, P Washington, O Devinsky, E Bromfield, R J Porter, F J Nice. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia. 1991 Jan; 32(1):130-2. doi: 10.1111/j.1528-1157.1991.tb05624.x. [PMID: 1985822]
  • R Hartley, M D Lucock, P C Ng, W I Forsythe, B McLain, C J Bowmer. Factors influencing plasma level/dose ratios of carbamazepine and its major metabolites in epileptic children. Therapeutic drug monitoring. 1990 Sep; 12(5):438-44. doi: 10.1097/00007691-199009000-00006. [PMID: 2293405]
  • J J Muñoz, R E De Salamanca, C Diaz-Obregón, F L Timoneda. The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites. British journal of clinical pharmacology. 1990 Jun; 29(6):763-5. doi: 10.1111/j.1365-2125.1990.tb03699.x. [PMID: 2378792]
  • E Mendez-Alvarez, R Soto-Otero, J Galan-Valiente, G Sierra-Marcuño. Effect of phenobarbital on carbamazepine and its major metabolites in serum, different brain areas, and urine after acute and chronic administration to rats. Epilepsia. 1990 Mar; 31(2):202-10. doi: 10.1111/j.1528-1167.1990.tb06307.x. [PMID: 2318171]
  • L E Riad, R J Sawchuk. Simultaneous determination of carbamazepine and its epoxide and transdiol metabolites in plasma by microbore liquid chromatography. Clinical chemistry. 1988 Sep; 34(9):1863-6. doi: 10.1093/clinchem/34.9.1857. [PMID: 3416433]
  • R D Chelberg, S Gunawan, D M Treiman. Simultaneous high-performance liquid chromatographic determination of carbamazepine and its principal metabolites in human plasma and urine. Therapeutic drug monitoring. 1988; 10(2):188-93. doi: 10.1097/00007691-198802000-00013. [PMID: 3381237]
  • B Rambeck, T May, U Juergens. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Therapeutic drug monitoring. 1987 Sep; 9(3):298-303. doi: 10.1097/00007691-198709000-00008. [PMID: 3672573]
  • D K Robbins, S L Chang, R J Baumann, P J Wedlund. Quantitation of trans-10,11-dihydroxy-10,11-dihydrocarbamazepine in human urine by high-performance liquid chromatography. Journal of chromatography. 1987 Mar; 415(1):208-13. doi: 10.1016/s0378-4347(00)83212-0. [PMID: 3584359]
  • G E von Unruh, W D Paar. Gas chromatographic/mass spectrometric assays for oxcarbazepine and its main metabolites, 10-hydroxy-carbazepine and carbazepine-10,11-trans-diol. Biomedical & environmental mass spectrometry. 1986 Dec; 13(12):651-6. doi: 10.1002/bms.1200131203. [PMID: 2952188]
  • G van Belle, P N Friel. Problem of spurious correlation in the evaluation of steady-state carbamazepine levels using metabolite data. Therapeutic drug monitoring. 1986; 8(2):177-83. doi: 10.1097/00007691-198606000-00009. [PMID: 3726931]
  • T B Vree, T J Janssen, Y A Hekster, E F Termond, A C van de Dries, W J Wijnands. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. Therapeutic drug monitoring. 1986; 8(3):297-304. doi: 10.1097/00007691-198609000-00011. [PMID: 3750374]
  • A Kumps, Y Mardens. Cross-reactivity assessment of oxcarbazepine and its metabolites in the EMIT assay of carbamazepine plasma levels. Therapeutic drug monitoring. 1986; 8(1):95-7. doi: 10.1097/00007691-198603000-00015. [PMID: 3515642]
  • B F Bourgeois, N Wad. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children. Therapeutic drug monitoring. 1984; 6(3):259-65. doi: 10.1097/00007691-198409000-00001. [PMID: 6506133]
  • H K Hundt, A K Aucamp, F O Müller. Pharmacokinetic aspects of carbamazepine and its two major metabolites in plasma during overdosage. Human toxicology. 1983 Oct; 2(4):607-14. doi: 10.1177/096032718300200405. [PMID: 6642517]
  • H K Hundt, A K Aucamp, F O Müller, M A Potgieter. Carbamazepine and its major metabolites in plasma: a summary of eight years of therapeutic drug monitoring. Therapeutic drug monitoring. 1983; 5(4):427-35. doi: 10.1097/00007691-198312000-00009. [PMID: 6659015]
  • P Hernuss, E Müller Tyl, H Salzer, H Sinzinger, L Wicke, T Prey, L Reisinger. [Pollen diet as an adjuvans of radiotherapy in gynecologic carcinomas]. Strahlentherapie. 1975 Nov; 150(5):500-6. doi: NULL. [PMID: 2995]